ESTUDIO OBSERVACIONAL RETROSPECTIVO Y PROSPECTIVO SOBRE EL MANEJO DEL TRATAMIENTO DE SOPORTE EN LOS PACIENTES CON LINFOMA NO HODGKIN TRATADOS CON CHOP-14 O CHOP-21 (CON O SIN RITUXIMAB)

Datos básicos

Protocolo:
AMG-LNH-2007-01
EUDRACT:
NO PROCEDE
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Año de incio:
Año de finalización:
ESTUDIO OBSERVACIONAL

Documentos

  • No hay documentos

Participantes

Grupos

Resultados del Ensayo Clínico


18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study.

Cordoba, Raul; (...); Martin Garcia-Sancho, Alejandro

Article. 10.1080/17474086.2024.2313457. 2024

  • Open Access.

A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL).

Martínez-Banaclocha N; (...); Gumà J

Article. 10.3390/cancers16051034. 2024

  • Open Access.

A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study.

Martínez-Trufero J; (...); Gutiérrez A

Article. 10.3390/cancers13040792. 2021

  • Open Access.

CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.

Hontecillas-Prieto L; (...); de la Cruz-Merino L

Article. 10.3389/fimmu.2024.1293931. 2024

  • Open Access.

CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study

Frezza, Anna Maria; (...); Gronchi, Alessandro

Article. 10.1002/cam4.5015. 2022

  • Open Access.

Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial

Jimenez-Cortegana, C; (...); de la Cruz-Merino, L

Article. 10.1136/jitc-2020-002323. 2021

  • Open Access.

Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.

Rodriguez-Pinilla SM; (...); Cordoba, Raul

Article. 10.1111/bjh.16741. 2021

  • Open Access.

Clinical Characteristics and Management of Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: A Feasibility Analysis of Electronic Health Records Using Natural Language Processing.

Ortiz A; (...); Rodriguez M

Article. 10.1159/000528784. 2023

  • Open Access.

Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study.

Ochenduszko, Sebastian; (...); Maiques, Inmaculada Maestu

Article. 10.1111/pcmr.13093. 2023

  • Open Access.

Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.

Simarro J; (...); Palanca S

Article. 10.3390/cancers11081196. 2019

  • Open Access.

Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002-BECARE)

Soria, A.; (...); Cerezuela-Fuentes, P.

Meeting Abstract. 10.1016/j.annonc.2023.09.2248. 2023

  • Open Access.

Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).

Marquez-Rodas, Ivan; (...); Berrocal, Alfonso

Article. 10.1093/neuonc/noae116. 2024

  • Open Access.

Final results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: Study PANTERA

Trufero, JM; (...); Cruz-Hernandez, J

Meeting Abstract. 2019


First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma

Gonzalez, J. A.; (...); Lopez Pousa, A.

Meeting Abstract. 10.1016/j.annonc.2023.09.1161. 2023

  • Open Access.

First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas

Gonzalez-Lopez, Jose Antonio; (...); Pousa, Antonio Lopez

Meeting Abstract. https://doi.org/10.1016/j.annonc.2023.09.1161. 2024

  • Open Access.

ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma

Martin Broto, Javier; (...); Hindi, Nadia

Meeting Abstract. 2023


Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital.

Simarro, Javier; (...); Palanca, Sarai

Article. 10.3390/cancers15061705. 2023

  • Open Access.

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.

Gonzalez-Cao M; (...); Berrocal A

Article. 10.1038/s41467-021-26572-6. 2021

  • Open Access.

Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial

Marquez-Rodas, I; (...); Berrocal, A

Meeting Abstract. 10.1016/j.annonc.2021.08.1423. 2021

  • Open Access.

Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker subanalysis.

Palaz N-Carri N, Natalia; (...); de la Cruz-Merino, Luis

Article. 10.1158/1078-0432.CCR-22-0588. 2022

  • Open Access.

Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial.

Merino, LD; (...); Dominguez, AR

Meeting Abstract. 2020


Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.

González-Barca E; (...); de Sevilla AF

Article. 10.1007/s00277-020-04056-9. 2020


Multicenter real-world data of treatment with NALIRI plus 5FU/LV in advanced Spanish pancreatic cancer

Alvarez Gallego, R.; (...); Cubillo, A.

Meeting Abstract. 10.1016/j.annonc.2023.04.238. 2023


Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)

Franco, F; (...); Provencio, M

Article. 10.3390/curroncol28020118. 2021

  • Open Access.

Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG).

Gronchi, Alessandro; (...); Casali, Paolo Giovanni

Article. 10.1200/JCO.23.00908. 2024


Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.

Pasquali, Sandro; (...); Gronchi, Alessandro

Article. 10.1002/cncr.33895. 2022

  • Open Access.

Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups

Gronchi, A; (...); Casali, PG

Article. 10.1200/JCO.19.03289. 2020

  • Open Access.

Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Results of the expanded cohort of myxoid liposarcoma of the randomized clinical trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).

Gronchi, Alessandro; (...); Casali, Paolo Giovanni

Meeting Abstract. 2022


Opioid-Induced Constipation in Oncological Patients: New Strategies of Management.

Mesía R; (...); Pujol E

Article. 10.1007/s11864-019-0686-6. 2019

  • Open Access.

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).

Isla D; (...); Provencio M

Article. 10.1016/j.lungcan.2018.11.041. 2019


Pain Standards for Accredited Healthcare Organizations (ACDON Project): A Mixed Methods Study.

Perez, Concepcion; (...); Mira, Jose J.

Article. 10.3390/jpm11020102. 2021

  • Open Access.

Pancreatic cancer, Radiomics and Artificial Intelligence: A Review.

Marti-Bonmati L; (...); Alberich-Bayarri A

Article. 10.1259/bjr.20220072. 2022


Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.

Martin Garcia-Sancho, Alejandro; (...); Cordoba, Raul

Article. 10.1111/bjh.18941. 2023

  • Open Access.

Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol

Salazar, Juliana; (...); Sebio, Ana

Article. 10.3390/pharmaceutics16121585. 2024

  • Open Access.

Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS).

Martin-Broto J; (...); Hindi N

Article. 10.1200/JCO.24.00358. 2024


Phase II trial of palbociclib in advanced sarcoma overexpressing CDK4 gene excluding dedifferentiated liposarcoma (DD LPS): A study from the Spanish Group for Research on Sarcoma (GEIS).

Broto, Javier Martin; (...); Hindi, Nadia

Meeting Abstract. 2022


Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.

Pedrosa, Lucia; (...); Sanchez-Beato, Margarita

Article. 10.1038/s41598-020-80376-0. 2021

  • Open Access.

Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain

Alvarez-Gallego, Rafael; (...); Cubillo, Antonio

Article. 10.1177/17588359241309828. 2025

  • Open Access.

Real-world study on characteristics of advanced melanoma patients with sustained complete response (CR) after elective 1st line anti-programmed death-1 (anti-PD1) monotherapy discontinuation.

Ochenduszko, Sebastian; (...); Maestu, Inmaculada

Meeting Abstract. 2022


Redefining radiologic responses (RR) in solid tumors: Shall we brace ourselves for a post-RECIST era? Results from a randomized clinical trial (RCT) on neoadjuvant chemotherapy in high-risk soft-tissue sarcomas (HR-STS) of the trunk or extremities

Vanzulli, Andrea; (...); Gronchi, Alessandro

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.11553. 2024

  • Open Access.

Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.

Vanzulli, A; (...); Gronchi, A

Article. 10.1016/j.esmoop.2025.104299. 2025

  • Open Access.

Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.

Gonzalez-Cao, Maria; (...); Berrocal, Alfonso

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.9528. 2021


RT after Encorafenib and Binimetinib on BRAF mutated melanoma brain metastases. GEM1802-Phase II

Alvarez, A.; (...); Marquez Rodas, I.

Meeting Abstract. 2023


Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.

Gounder, Mrinal M.; (...); Attia, Steven

Article. 10.1200/JCO.21.01829. 2022

  • Open Access.

SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022).

Guma, Josep; (...); Provencio, Mariano

Article. 10.1007/s12094-023-03206-5. 2023

  • Open Access.

Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy.

Pasquali, Sandro; (...); Gronchi, Alessandro

Article. 10.1016/j.ebiom.2024.105220. 2024

  • Open Access.

Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients

Simarro, Javier; (...); Palanca, Sarai

Article. 10.3390/ijms23158526. 2022

  • Open Access.

Campos de Estudio

Compartir